How to work with us

HOOKIPA is dedicated to using the full potential of our proprietary arenavirus platform.

Our technology is designed to produce a stronger immune response that enables HOOKIPA to develop immuno-oncology therapies and therapeutic vaccines.

We have forged a partnership with Gilead to develop immunotherapies against HIV and Hepatitis B. To learn more about our partnership with Gilead please see this Press Release.

We are open for further strategic partnerships which reflect the potential of the technology, provide performance related downstream revenues while preserving growth opportunities for HOOKIPA in the future.

Please contact our Business Development & Licensing Team with any inquiries.

We look forward to hearing from you!